News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
412,507 Results
Type
Article (20178)
Company Profile (138)
Press Release (392191)
Multimedia
Podcasts (81)
Webinars (13)
Section
Business (132717)
Career Advice (1389)
Deals (23553)
Drug Delivery (87)
Drug Development (45203)
Employer Resources (140)
FDA (8874)
Job Trends (9866)
News (216630)
Policy (19689)
Tag
Academia (991)
Accelerated approval (3)
Adcomms (9)
Allergies (42)
Alliances (35303)
ALS (50)
Alzheimer's disease (650)
Antibody-drug conjugate (ADC) (68)
Approvals (8904)
Artificial intelligence (205)
Autoimmune disease (13)
Automation (11)
Bankruptcy (190)
Best Places to Work (7303)
BIOSECURE Act (18)
Biosimilars (67)
Biotechnology (72)
Bladder cancer (33)
Brain cancer (18)
Breast cancer (130)
Cancer (1071)
Cardiovascular disease (89)
Career advice (1168)
Career pathing (25)
CAR-T (63)
Cell therapy (210)
Cervical cancer (10)
Clinical research (37825)
Collaboration (563)
Compensation (227)
Complete response letters (17)
COVID-19 (1155)
CRISPR (30)
C-suite (199)
Cystic fibrosis (58)
Data (1002)
Decentralized trials (1)
Denatured (35)
Depression (21)
Diabetes (124)
Diagnostics (3355)
Digital health (10)
Diversity (7)
Diversity, equity & inclusion (31)
Drug discovery (84)
Drug pricing (95)
Drug shortages (18)
Duchenne muscular dystrophy (50)
Earnings (46403)
Editorial (33)
Employer branding (17)
Employer resources (117)
Events (59294)
Executive appointments (614)
FDA (9583)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (420)
Gene editing (63)
Generative AI (20)
Gene therapy (176)
GLP-1 (459)
Government (2217)
Grass and pollen (4)
Guidances (44)
Healthcare (8331)
Huntington's disease (9)
IgA nephropathy (16)
Immunology and inflammation (46)
Indications (18)
Infectious disease (1224)
Inflammatory bowel disease (71)
Inflation Reduction Act (10)
Influenza (33)
Intellectual property (67)
Interviews (220)
IPO (9286)
IRA (44)
Job creations (2854)
Job search strategy (1009)
Kidney cancer (7)
Labor market (32)
Layoffs (246)
Leadership (17)
Legal (4681)
Liver cancer (34)
Lung cancer (158)
Lymphoma (85)
Machine learning (6)
Management (44)
Manufacturing (254)
MASH (48)
Medical device (5927)
Medtech (5931)
Mergers & acquisitions (14689)
Metabolic disorders (377)
Multiple sclerosis (32)
NASH (14)
Neurodegenerative disease (44)
Neuropsychiatric disorders (12)
Neuroscience (926)
NextGen: Class of 2025 (3644)
Non-profit (1505)
Now hiring (19)
Obesity (206)
Opinion (215)
Ovarian cancer (42)
Pain (62)
Pancreatic cancer (28)
Parkinson's disease (71)
Partnered (15)
Patents (162)
Patient recruitment (48)
Peanut (12)
People (44131)
Pharmaceutical (67)
Pharmacy benefit managers (18)
Phase I (10434)
Phase II (16295)
Phase III (13812)
Pipeline (706)
Policy (132)
Postmarket research (1531)
Preclinical (4284)
Press Release (60)
Prostate cancer (59)
Psychedelics (14)
Radiopharmaceuticals (173)
Rare diseases (240)
Real estate (4279)
Recruiting (59)
Regulatory (13993)
Reports (33)
Research institute (1078)
Resumes & cover letters (227)
Rett syndrome (2)
RNA editing (3)
RSV (13)
Schizophrenia (47)
Series A (76)
Series B (41)
Service/supplier (5)
Sickle cell disease (36)
Special edition (12)
Spinal muscular atrophy (90)
Sponsored (21)
Startups (2507)
State (2)
Stomach cancer (5)
Supply chain (52)
Tariffs (42)
The Weekly (44)
Vaccines (251)
Venture capitalists (27)
Weight loss (134)
Women's health (23)
Worklife (14)
Date
Today (81)
Last 7 days (474)
Last 30 days (1452)
Last 365 days (18517)
2025 (6212)
2024 (19870)
2023 (22822)
2022 (31491)
2021 (33268)
2020 (31907)
2019 (27865)
2018 (21195)
2017 (20624)
2016 (19598)
2015 (22867)
2014 (18024)
2013 (15488)
2012 (17074)
2011 (17612)
2010 (15552)
Location
Africa (508)
Alabama (22)
Alaska (5)
Arizona (106)
Arkansas (5)
Asia (34841)
Australia (4756)
California (3034)
Canada (1315)
China (368)
Colorado (121)
Connecticut (149)
Delaware (75)
Europe (57868)
Florida (501)
Georgia (84)
Idaho (31)
Illinois (372)
India (19)
Indiana (197)
Iowa (7)
Japan (142)
Kansas (79)
Kentucky (18)
Louisiana (8)
Maine (16)
Maryland (458)
Massachusetts (2319)
Michigan (128)
Minnesota (198)
Mississippi (2)
Missouri (41)
Montana (13)
Nebraska (19)
Nevada (22)
New Hampshire (43)
New Jersey (1132)
New Mexico (13)
New York (956)
North Carolina (633)
North Dakota (7)
Northern California (1285)
Ohio (119)
Oklahoma (10)
Oregon (22)
Pennsylvania (702)
Puerto Rico (8)
Rhode Island (18)
South America (824)
South Carolina (17)
Southern California (1178)
Tennessee (52)
Texas (406)
United States (12264)
Utah (83)
Virginia (103)
Washington D.C. (44)
Washington State (197)
West Virginia (3)
Wisconsin (36)
412,507 Results for "taro pharmaceutical industries ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary General Meeting”), to be held on May 22, 2024, at 10:00 a.m., Israel time.
April 15, 2024
·
7 min read
Deals
Sun Pharma Completes Taro Merger
Sun Pharmaceutical Industries Limited today announced the successful completion of the merger of Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) with its subsidiary.
June 24, 2024
·
1 min read
Deals
Taro Shareholders Approve Merger with Sun Pharma
Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024.
May 23, 2024
·
4 min read
Biotech Beach
Taro Provides Results for Year Ended March 31, 2024
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2024.
May 20, 2024
·
9 min read
Business
Taro to Release Full Year Results on May 20, 2024
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for year ended March 31, 2024, after the close of market on Monday, May 20, 2024.
May 15, 2024
·
1 min read
Biotech Beach
Taro Provides Results for December 31, 2023
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and nine months ended December 31, 2023.
January 25, 2024
·
10 min read
Deals
Taro Announces Merger Agreement with Sun Pharma
Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.
January 17, 2024
·
8 min read
Business
Taro Provides Results for September 30, 2023
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023.
October 26, 2023
·
9 min read
Business
Taro to Release Third Quarter Results on January 25, 2024
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024.
January 19, 2024
·
1 min read
Business
Taro to Release Second Quarter Results on October 26, 2023
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023.
October 19, 2023
·
1 min read
1 of 41,251
Next
